These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 8639263)

  • 1. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
    Nebert DW; McKinnon RA; Puga A
    DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer.
    Neber DW; Roe AL
    Sci Total Environ; 2001 Jul; 274(1-3):93-102. PubMed ID: 11453308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
    Ozawa S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
    Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
    Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
    Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
    Roots I; Brockmöller J; Drakoulis N; Loddenkemper R
    Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic factors in individual responses to environmental exposures.
    Hirvonen A
    J Occup Environ Med; 1995 Jan; 37(1):37-43. PubMed ID: 7620941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
    Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
    Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
    Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
    Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of genetic polymorphisms of drug metabolism.
    Meyer UA; Zanger UM
    Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
    Wadelius M; Autrup JL; Stubbins MJ; Andersson SO; Johansson JE; Wadelius C; Wolf CR; Autrup H; Rane A
    Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women.
    Zgheib NK; Shamseddine AA; Geryess E; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; El-Saghir NS
    Mutat Res; 2013; 747-748():40-7. PubMed ID: 23628324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
    Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
    Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
    Brockmöller J; Cascorbi I; Kerb R; Roots I
    Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
    Suzuki S; Muroishi Y; Nakanishi I; Oda Y
    J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays.
    Zhao B; Lee EJ; Wong JY; Yeoh PN; Gong NH
    Pharmacogenetics; 1995 Oct; 5(5):275-80. PubMed ID: 8563767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
    Daly AK; Cholerton S; Armstrong M; Idle JR
    Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):55-61. PubMed ID: 7698086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetic and phenotypic polymorphisms in carcinogen-metabolizing enzymes and cancer susceptibility].
    Watanabe M
    Nihon Rinsho; 1996 Aug; 54(8):2261-75. PubMed ID: 8810806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants.
    Nebert DW
    Clin Chem Lab Med; 2000 Sep; 38(9):857-61. PubMed ID: 11097340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic polymorphisms and cancer susceptibility.
    Smith G; Stanley LA; Sim E; Strange RC; Wolf CR
    Cancer Surv; 1995; 25():27-65. PubMed ID: 8718512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.